Showing 2021-2030 of 5697 results for "".
- Aerie Pharmaceuticals Announces the Appointment of David A. Hollander, MD, MBA, as Chief Research & Development Officerhttps://modernod.com/news/aerie-pharmaceuticals-announces-the-appointment-of-david-a-hollander-md-mba-as-chief-research-development-officer/2477056/Aerie Pharmaceuticals announced the appointment of David A. Hollander, MD, MBA, as Chief Research & Development Officer, an executive officer position reporting to Vicente Anido, Jr., PhD, Aerie’s Chairman and Chief Executive Officer. Dr. Hollander will commence his employment at Aerie on Nov
- NovaBay Pharmaceuticals to Distribute the NuLids System for the Treatment of Dry Eye in Certain U.S. Geographieshttps://modernod.com/news/novabay-pharmaceuticals-to-distribute-the-nulids-system-for-the-treatment-of-dry-eye-in-certain-u-s-geographies/2477048/NovaBay Pharmaceuticals announced an exclusive 90-day agreement with NuSight Medical to distribute the NuLids System for treatment of blepharitis and dry eye in six of NovaBay’s top-performing territories. The NuLids System is a hand-held, cordless device that safely and effectively removes accum
- SightGlass Vision to Present New Data on its Novel Lenses to Control Nearsightedness in Children at 3rd World Congress of Optometryhttps://modernod.com/news/sightglass-vision-to-present-new-data-on-its-novel-lenses-to-control-nearsightedness-in-children-at-3rd-world-congress-of-optometry/2477040/SightGlass Vision announced that data from three clinical trials overviewing discovery to clinical development of its novel spectacle lenses will be presented for the first time in a scientific forum at the 3rd World Congress of Optometry (WCO19) and Academy 2019 (Academy19), held
- Allegro to Present Clinical Research on the Novel Integrin-Regulating Portfolio at AAOhttps://modernod.com/news/allegro-to-present-clinical-research-on-the-novel-integrin-regulating-portfolio-at-aao/2476956/Allegro Ophthalmics announced that the results of its phase 2 clinical study of risuteganib (Luminate) for the treatment of intermediate nonexudative age-related macular degeneration (AMD) will be presented during AAO
- Novartis Receives FDA Approval for Beovu for Wet AMDhttps://modernod.com/news/novartis-receives-fda-approval-for-beovu-for-wet-amd/2476953/Novartis announced that the FDA approved Beovu (brolucizumab-dbll) injection, also known as RTH258, for the treatment of wet age-related macular degeneration (AMD). Beovu is the first FDA approved anti-VEGF to offer both greater fluid resolution versus aflibercept and the ability to maintain elig
- Konan Medical’s EyeKinetix Pupillograph is Now Available in the United Stateshttps://modernod.com/news/konan-medicals-eyekinetix-pupillograph-is-now-available-in-the-united-states/2476902/Konan Medical announced that EyeKinetix is FDA listed and now available for sale in the United States. EyeKinetix is Konan’s 2nd generation pupillograph, which is smaller, faster, easier to use and less expensive than its predecessor, RAPDx, a device that brought key pupillary testin
- SightGlass Vision to Present Pivotal Clinical Trial Baseline Data Evaluating Novel Lenses to Control Nearsightedness in Childrenhttps://modernod.com/news/sightglass-vision-to-present-pivotal-clinical-trial-baseline-data-evaluating-novel-lenses-to-control-nearsightedness-in-children/2476876/SightGlass Vision announced that baseline data from CYPRESS, the company’s pivotal trial assessing the safety and efficacy of novel lenses designed to control nearsightedness in children, will be presented at the 17th International Myopia Conference 2019, held
- Macular Degeneration Conference Series in the Spotlighthttps://modernod.com/news/macular-degeneration-conference-series-in-the-spotlight/2476865/Part of the 2019 Macular Degeneration Association Educational Conference Series will take place on Saturday, September 21, at the Doubletree Chicago North Shore Conference Center Skokie, Illinois. The conference, “Eyes on Sight,” is aimed to deliver the most up-to-date research regarding t
- NHS England to Fund Novartis’ Gene Therapy Luxturna for Inherited Retinal Diseasehttps://modernod.com/news/nhs-england-to-fund-novartis-gene-therapy-luxturna-for-inherited-retinal-disease/2476855/NHS England announced Wednesday funding for Novartis’ Luxturna (voretigene neparvovec) after agreeing a deal with the company that will provide access to the gene therapy from January 2020. The one-time treatment gained European Commission approval last year for patients with vision loss du
- Now Optics Names Two Women to its Executive Leadership Teamhttps://modernod.com/news/now-optics-names-two-women-to-its-executive-leadership-team/2476834/Now Optics recently named two women to its leadership team. Former CVS Health’s Morgan Diaz joined Now Optics as senior vice president of operations and business development, and Lukana Justin previously from Office Depot Inc. is the new, senior vice president of marketing. They join Tara Pellegr